Deutsche Bank upgrades Roche to Buy with 500 CHF target

Deutsche Bank Research has upgraded the Swiss pharmaceutical company Roche from “Hold” to “Buy,” significantly raising its price target from 340 to 500 Swiss francs.

Analyst Emmanuel Papadakis attributed the recommendation to positive feedback from physicians regarding Giredestrant, based on a recent oncology survey. The analyst noted that while the timing of the upgrade follows the market consensus, the medical feedback appears increasingly definitive, suggesting positive short- and medium-term implications while immediate risks have diminished.

Separately, broader market trends indicate a shift in investor interest toward the pharmaceutical sector. Following corrections in technology stocks, investors are increasingly seeking companies with predictable earnings and recession-resistant business models, such as those found in the pharmaceutical and biotechnology industries.